
## Mark H Stoler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1311500/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology, The, 2005, 6, 271-278.	5.1	1,400
2	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Ca-A Cancer Journal for Clinicians, 2012, 62, 147-172.	157.7	1,022
3	Interobserver Reproducibility of Cervical Cytologic and Histologic Interpretations <subtitle>Realistic Estimates From the ASCUS-LSIL Triage Study</subtitle> . JAMA - Journal of the American Medical Association, 2001, 285, 1500.	3.8	952
4	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 2012, 137, 516-542.	0.4	686
5	The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Archives of Pathology and Laboratory Medicine. 2012. 136. 1266-1297.	1.2	548
6	The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated Lesions. International Journal of Gynecological Pathology, 2013, 32, 76-115.	0.9	454
7	Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Gynecologic Oncology, 2015, 136, 189-197.	0.6	442
8	Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncology, The, 2011, 12, 880-890.	5.1	440
9	p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2002, 26, 1389-1399.	2.1	425
10	Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Human Pathology, 1992, 23, 117-128.	1.1	416
11	The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions. Journal of Lower Genital Tract Disease, 2012, 16, 205-242.	0.9	399
12	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet, The, 2017, 390, 2143-2159.	6.3	314
13	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Journal of Lower Genital Tract Disease, 2012, 16, 175-204.	0.9	310
14	High-Risk Human Papillomavirus Testing in Women With ASC-US Cytology. American Journal of Clinical Pathology, 2011, 135, 468-475.	0.4	304
15	Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology, 1989, 172, 331-340.	1.1	237
16	Using Biomarkers as Objective Standards in the Diagnosis of Cervical Biopsies. American Journal of Surgical Pathology, 2010, 34, 1077-1087.	2.1	233
17	The ATHENA human papillomavirus study: design, methods, and baseline results. American Journal of Obstetrics and Gynecology, 2012, 206, 46.e1-46.e11.	0.7	221
18	Small-Cell Neuroendocrine Carcinoma of the Cervix. American Journal of Surgical Pathology, 1991, 15, 28-32.	2.1	219

#	Article	IF	CITATIONS
19	In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and a cervical carcinoma. Human Pathology, 1986, 17, 1250-1258.	1.1	209
20	Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology-Negative Results. American Journal of Clinical Pathology, 2011, 136, 578-586.	0.4	207
21	Toward Objective Quality Assurance in Cervical Cytopathology: <i>Correlation of Cytopathologic Diagnoses with Detection of High-risk Human Papillomavirus Types</i> . American Journal of Clinical Pathology, 1994, 102, 182-187.	0.4	200
22	Human Papillomaviruses and Cervical Neoplasia: A Model for Carcinogenesis. International Journal of Gynecological Pathology, 2000, 19, 16-28.	0.9	189
23	The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses. American Journal of Clinical Pathology, 2007, 127, 805-815.	0.4	186
24	The Expanded Use of HPV Testing in Gynecologic Practice per ASCCP-Guided Management Requires the Use of Well-Validated Assays. American Journal of Clinical Pathology, 2007, 127, 335-337.	0.4	140
25	The accuracy of colposcopic biopsy: Analyses from the placebo arm of the Gardasil clinical trials. International Journal of Cancer, 2011, 128, 1354-1362.	2.3	135
26	Differential Expression and Regulation of Estrogen Receptors (ERs) in Rat Pituitary and Cell Lines: Estrogen Decreases ERα Protein and Estrogen Responsiveness*. Endocrinology, 2000, 141, 2174-2184.	1.4	108
27	Consensus Conference on Second Opinions in Diagnostic Anatomic Pathology. American Journal of Clinical Pathology, 2000, 114, 329-335.	0.4	100
28	Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecologic Oncology, 2017, 144, 51-56.	0.6	98
29	Special Commentary. American Journal of Clinical Pathology, 2010, 134, 193-199.	0.4	92
30	A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. Gynecologic Oncology, 2018, 148, 422-429.	0.6	81
31	Lower cost strategies for triage of human papillomavirus DNAâ€positive women. International Journal of Cancer, 2014, 134, 2891-2901.	2.3	80
32	Interlaboratory variation in the performance of liquid-based cytology: Insights from the ATHENA trial. International Journal of Cancer, 2014, 134, 1835-1843.	2.3	74
33	Human Papillomavirus Messenger RNA Expression in Adenocarcinoma In Situ of the Uterine Cervix. International Journal of Gynecological Pathology, 1989, 8, 321-330.	0.9	71
34	Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesionsâ~†. Human Pathology, 1994, 25, 343-348.	1.1	66
35	Advances in Cervical Screening Technology. Modern Pathology, 2000, 13, 275-284.	2.9	62
36	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Modern Pathology, 2017, 30, 1622-1632.	2.9	62

#	Article	IF	CITATIONS
37	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology, 2019, 154, 110-117.	0.6	62
38	Diagnostic Utility of Endocervical Curettage in Women Undergoing Colposcopy for Equivocal or Low-Grade Cytologic Abnormalities. Obstetrics and Gynecology, 2007, 110, 288-295.	1.2	59
39	Detection of Infection by Human Papillomavirus in Genital Condylomata: A Comparison Study Using Immunocytochemistry and <i>In Situ</i> Nucleic Acid Hybridization. American Journal of Clinical Pathology, 1988, 89, 505-510.	0.4	57
40	Human Papillomavirus Type 6 in Grade I Transitional Cell Carcinoma of the Urethra. Journal of Urology, 1990, 143, 126-128.	0.2	55
41	Relevance of Random Biopsy at the Transformation Zone When Colposcopy Is Negative. Obstetrics and Gynecology, 2014, 124, 670-678.	1.2	55
42	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncology, The, 2020, 21, 1643-1652.	5.1	54
43	APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. American Journal of Obstetrics and Gynecology, 2013, 208, 144.e1-144.e8.	0.7	53
44	The Interplay of Age Stratification and HPV Testing on the Predictive Value of ASC-US Cytology. American Journal of Clinical Pathology, 2012, 137, 295-303.	0.4	52
45	Human Papillomavirus Oncogenic mRNA Testing for Cervical Cancer Screening. American Journal of Clinical Pathology, 2015, 144, 473-483.	0.4	51
46	The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results. Gynecologic Oncology, 2018, 149, 498-505.	0.6	51
47	Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infectious Diseases, The, 2022, 22, 413-425.	4.6	50
48	The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status. American Journal of Surgical Pathology, 2015, 39, 729-736.	2.1	48
49	Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer, 2002, 96, 14-20.	2.0	45
50	Longitudinal Evaluation of Interobserver and Intraobserver Agreement of Cervical Intraepithelial Neoplasia Diagnosis Among an Experienced Panel of Gynecologic Pathologists. American Journal of Surgical Pathology, 2007, 31, 1854-1860.	2.1	44
51	ExÂvivo lung perfusion with adenosine A2A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 538-546.	0.4	44
52	The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5†years of follow-up. Gynecologic Oncology, 2019, 153, 521-529.	0.6	43
53	<scp>PD</scp> ‣1 and <scp>IDO</scp> expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology, 2019, 74, 256-268.	1.6	42
54	Chemokine expression in trinitrochlorobenzene-mediated contact hypersensitivity. Journal of Leukocyte Biology, 1994, 55, 452-460.	1.5	41

#	Article	IF	CITATIONS
55	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade–specific epigenome and transcriptome landscapes. Nature Genetics, 2020, 52, 800-810.	9.4	40
56	Risk Stratification By p16 Immunostaining of CIN1 Biopsies. American Journal of Surgical Pathology, 2015, 39, 611-617.	2.1	39
57	Airway pressure release ventilation during exÂvivo lung perfusion attenuates injury. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 197-204.	0.4	39
58	New Bethesda Terminology and Evidence-Based Management Guidelines for Cervical Cytology Findings. JAMA - Journal of the American Medical Association, 2002, 287, 2140.	3.8	38
59	Lungs donated after circulatory death and prolonged warm ischemia are transplanted successfully after enhanced exÂvivo lung perfusion using adenosine A2B receptor antagonism. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1811-1820.	0.4	38
60	Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25†years of age, with NILM cytology. Gynecologic Oncology, 2019, 153, 26-33.	0.6	37
61	Differential Expression and Regulation of Estrogen Receptors (ERs) in Rat Pituitary and Cell Lines: Estrogen Decreases ERα Protein and Estrogen Responsiveness. , 0, .		37
62	Human Papillomavirus Genotype-Specific Prevalence across the Continuum of Cervical Neoplasia and Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 230-240.	1.1	36
63	The "CD43 Only―Phenotype: <i>An Aberrant, Nonspecific Immunophenotype Requiring Comprehensive Analysis for Lineage Resolution</i> . American Journal of Clinical Pathology, 1992, 97, 861-865.	0.4	35
64	Effectiveness of novel, lower cost molecular human papillomavirusâ€based tests for cervical cancer screening in rural china. International Journal of Cancer, 2016, 138, 1453-1461.	2.3	35
65	Precursor langerhans cell histiocytosis. Cancer, 1992, 70, 547-553.	2.0	34
66	Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1053-1059.	1.1	34
67	Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21†years of age, with ASC-US or LSIL cytology. Gynecologic Oncology, 2019, 154, 360-367.	0.6	34
68	Clinical Performance of the BD Onclarity HPV Assay Using an Adjudicated Cohort of BD SurePath Liquid-Based Cytology Specimens. American Journal of Clinical Pathology, 2014, 142, 43-50.	0.4	33
69	Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years. Journal of Clinical Microbiology, 2015, 53, 2798-2804.	1.8	33
70	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	157.7	33
71	Detection of Human Papillomavirus 16, 18, and 45 in Women With ASC-US Cytology and the Risk of Cervical Precancer. American Journal of Clinical Pathology, 2015, 143, 160-167.	0.4	32
72	Routine Use of Adjunctive p16 Immunohistochemistry Improves Diagnostic Agreement of Cervical Biopsy Interpretation. American Journal of Surgical Pathology, 2018, 42, 1001-1009.	2.1	32

#	Article	IF	CITATIONS
73	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Archives of Pathology and Laboratory Medicine, 2020, 144, 725-734.	1.2	30
74	Human Papillomavirus Biology and Cervical Neoplasia: Implications for Diagnostic Criteria and Testing. Archives of Pathology and Laboratory Medicine, 2003, 127, 935-939.	1.2	30
75	Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. European Journal of Cancer, 2013, 49, 2179-2186.	1.3	29
76	Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Kiâ€67 dualâ€stained cytology—Retrospective insights from ATHENA. International Journal of Cancer, 2020, 146, 2599-2607.	2.3	29
77	Concomitant delineation of surface Ig, B-cell differentiation antigens, and HLADR on lymphoid proliferations using three-color immunocytometry. Cytometry, 1991, 12, 350-359.	1.8	28
78	Donation After Circulatory Death Lungs Transplantable Up to Six Hours After ExÂVivo Lung Perfusion. Annals of Thoracic Surgery, 2016, 102, 1845-1853.	0.7	28
79	Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. Modern Pathology, 2020, 33, 1182-1192.	2.9	28
80	The Role of Vascular Endothelial Growth Factor in the Tissue Specific in Vivo Growth of Prostate Cancer Cells. Growth Factors, 2001, 18, 287-302.	0.5	26
81	Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006–2015): a need for evidence-based policy. Risk Management and Healthcare Policy, 2017, Volume 10, 29-32.	1.2	25
82	Vendor-specific microbiome controls both acute and chronic murine lung allograft rejection by altering CD4+Foxp3+ regulatory T cell levels. American Journal of Transplantation, 2019, 19, 2705-2718.	2.6	25
83	Clinical validation of p16/Kiâ€67 dualâ€stained cytology triage of <scp>HPV</scp> â€positive women: Results from the <scp>IMPACT</scp> trial. International Journal of Cancer, 2022, 150, 461-471.	2.3	25
84	Human Papillomavirus Identified by Nucleic Acid Hybridization in Concomitant Nasal and Genital Papillomas. Laryngoscope, 1992, 102, 1014???1019.	1.1	23
85	Human papillomavirus testing for triage of women with lowâ€grade squamous intraepithelial lesions. International Journal of Cancer, 2013, 132, 959-966.	2.3	23
86	HPV E6/E7 mRNA In Situ Hybridization in the Diagnosis of Cervical Low-grade Squamous Intraepithelial Lesions (LSIL). American Journal of Surgical Pathology, 2018, 42, 192-200.	2.1	23
87	Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction. JCI Insight, 2019, 4, .	2.3	23
88	Eosinophils promote inducible NOSâ $\in$ "mediated lung allograft acceptance. JCI Insight, 2017, 2, .	2.3	22
89	Knowledge of Patients' Human Papillomavirus Status at the Time of Cytologic Review Significantly Affects the Performance of Cervical Cytology in the ATHENA Study. American Journal of Clinical Pathology, 2016, 146, 391-398.	0.4	21
90	CK7 Immunohistochemistry as a Predictor of CIN1 Progression. American Journal of Surgical Pathology, 2017, 41, 143-152.	2.1	21

#	Article	IF	CITATIONS
91	Testing for human papillomavirus: data driven implications for cervical neoplasia management. Clinics in Laboratory Medicine, 2003, 23, 569-583.	0.7	20
92	Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population. American Journal of Clinical Pathology, 2019, 151, 53-62.	0.4	20
93	The Virology of Cervical Neoplasia. Cancer Journal (Sudbury, Mass ), 2003, 9, 360-367.	1.0	19
94	A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry. Human Pathology, 2013, 44, 2542-2548.	1.1	19
95	HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology. American Journal of Clinical Pathology, 2019, 151, 433-442.	0.4	19
96	Does every little cell count? Don't ?ASCUS?. , 1999, 87, 45-47.		18
97	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine, 2015, 33, 2141-2151.	1.7	17
98	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. Journal of Infectious Diseases, 2019, 220, 1609-1619.	1.9	17
99	Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer, 2006, 108, 212-221.	2.0	16
100	A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4. Journal of Clinical Virology, 2016, 82, 145-151.	1.6	16
101	ExÂVivo Lung Perfusion Rehabilitates Sepsis-Induced Lung Injury. Annals of Thoracic Surgery, 2017, 103, 1723-1729.	0.7	16
102	InÂvivo lung perfusion rehabilitates sepsis-induced lung injury. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 440-448.e2.	0.4	15
103	HPV infections and cytologic abnormalities in vaccinated women 21–34†years of age: Results from the baseline phase of the Onclarity trial. Gynecologic Oncology, 2019, 153, 259-265.	0.6	15
104	Toward Objective Quality Assurance. American Journal of Clinical Pathology, 2002, 117, 520-522.	0.4	14
105	HPV Testing in Cervical Cytology Practice. Acta Cytologica, 2005, 49, 117-119.	0.7	14
106	From slide sets to sound bites: teaching and learning pathology in the digital age. Journal of the American Society of Cytopathology, 2014, 3, 183-187.	0.2	14
107	Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China. Journal of Clinical Microbiology, 2014, 52, 1954-1961.	1.8	14
108	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunology, Immunotherapy, 2019, 68, 1515-1526.	2.0	14

#	Article	IF	CITATIONS
109	Reduced-flow ex vivo lung perfusion to rehabilitate lungs donated after circulatory death. Journal of Heart and Lung Transplantation, 2020, 39, 74-82.	0.3	14
110	Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget, 2015, 6, 30194-30211.	0.8	14
111	The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. Journal of Clinical Virology, 2014, 61, 553-557.	1.6	13
112	The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. American Journal of Obstetrics and Gynecology, 2021, 225, 278.e1-278.e16.	0.7	12
113	Necrobiotic Pulmonary Nodules of Crohn's Disease in a Patient Receiving Vedolizumab. American Journal of Respiratory and Critical Care Medicine, 2019, 199, e1-e2.	2.5	10
114	Host Tumor Infiltrating Lymphocytes in B Cell Non-Hodgkin's Lymphomas. Leukemia and Lymphoma, 1993, 9, 85-90.	0.6	9
115	Role of histological findings and pathologic diagnosis for detection of human papillomavirus infection in men. Journal of Medical Virology, 2015, 87, 1777-1787.	2.5	9
116	Cutaneous beta human papillomaviruses and the development of male external genital lesions: A case-control study nested within the HIM Study. Virology, 2016, 497, 314-322.	1.1	8
117	Adjunct p16INK4a Immunohistochemistry Aids the Detection of High-Grade Squamous Intraepithelial Lesions in Endocervical Curettage Specimens. American Journal of Clinical Pathology, 2014, 141, 342-347.	0.4	7
118	Performance of an Human Papillomavirus Test in Samples From Women With Histolopathologically Confirmed Invasive Cervical Cancer. Journal of Lower Genital Tract Disease, 2016, 20, 151-153.	0.9	7
119	HPV RNA in situ hybridization can inform cervical cytologyâ€histology correlation. Cancer Cytopathology, 2018, 126, 533-540.	1.4	7
120	Frozen Sections of Cellular Lymphoid Proliferations Provide Adequate DNA for Routine Gene Rearrangement Analysis. American Journal of Clinical Pathology, 1991, 96, 360-363.	0.4	6
121	Adjunctive HPV In-Situ Hybridization (ISH) Assay as an Aid in the Diagnosis of Cervical Intraepithelial Neoplasia in Cervical Tissue Specimens. International Journal of Gynecological Pathology, 2012, 31, 588-595.	0.9	6
122	The Pathology of Cervical Neoplasia. Cancer Prevention, Cancer Causes, 2004, , 3-59.	0.3	6
123	The Impact of Human Papillomavirus Biology on the Clinical Practice of Cervical Pathology. , 2005, 10, 119-127.		5
124	Reversed Halo Sign. A Case of Cryptogenic Organizing Pneumonia with Spontaneous Resolution. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 109-110.	2.5	4
125	The CERTAIN Study Results. American Journal of Surgical Pathology, 2021, 45, 1348-1356.	2.1	4
126	Cervical precancer (intraepithelial neoplasia), including functional biomarkers and colposcopy. , 2009, , 189-226.		4

Mark H Stoler

#	Article	IF	CITATIONS
127	Two Siblings With Interstitial Lung Disease. Chest, 2018, 153, e75-e79.	0.4	3
128	Two Hours of In Vivo Lung Perfusion Improves Lung Function in Sepsis-Induced Acute Respiratory Distress Syndrome. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 337-346.	0.4	3
129	Patient Safety and the Next Generation of HPV DNA TestsThe Authors' ReplyPostscript. American Journal of Clinical Pathology, 2011, 135, 798-803.	0.4	2
130	The Pathology of Cervical Precancer and Cancer and its importance in clinical practice. , 2020, , 85-109.		2
131	Biomarkers and Their Role in Clarifying the Diagnosis and Clinical Management of Human Papillomavirus–Associated Lesions of the Lower Anogenital Tract. , 2013, 18, 168-176.		1
132	The pap smear caught it!: Harmonizing the findings of an abnormal pap smear and a right ovarian mass. Diagnostic Cytopathology, 2015, 43, 1039-1041.	0.5	1
133	A case report of a pulmonary metastasis of a polymorphous low-grade adenocarcinoma. Diagnostic Cytopathology, 2015, 43, 590-592.	0.5	0
134	Farewell. International Journal of Gynecological Pathology, 2015, 34, 1-2.	0.9	0
135	Cervical Squamous Intraepithelial Lesions. , 2017, , 91-114.		0